Douglas W. Beight

Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain

J. Scott Sawyer, Bryan D. Anderson, Douglas W. Beight et al. · Journal of Medicinal Chemistry · 2003 · 237 citations · Full text

Drug Target, Pyrazole-based Inhibitors, Pharmaceutical Chemistry +20

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan et al. · Oncotarget · 2017 · 168 citations · Full text

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

J. Scott Sawyer, Douglas W. Beight, Karen S. Britt et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 161 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Chemistry +9

Kinetic Characterization of Novel Pyrazole TGF-β Receptor I Kinase Inhibitors and Their Blockade of the Epithelial−Mesenchymal Transition

Sheng-Bin Peng, Lei Yan, Xiaoling Xia et al. · Biochemistry · 2005 · 99 citations

Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11

Gary A. Flynn, Douglas W. Beight, Shujaath Mehdi et al. · Journal of Medicinal Chemistry · 1993 · 67 citations · Full text

Cardiovascular Pharmacology, Altmetric Attention Score, Peptide Science +21